Jared Gollob
Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $9.1M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 1,510126,132 held (−1%) | $87.75 | $133K | +28.1% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 1,055125,077 held (−1%) | $88.50 | $93K | +27.0% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 3,048122,029 held (−2%) | $89.66 | $273K | +25.4% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 492121,537 held (−0%) | $84.00 | $41K | +33.8% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 2,519119,018 held (−2%) | $85.04 | $214K | +32.2% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 1,437117,581 held (−1%) | $85.78 | $123K | +31.0% |
| Mar 4SEC | KYMRKymera Therapeutics, Inc. | Sell | 447117,134 held (−0%) | $86.62 | $39K | +29.8% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 13,759145,540 held (−9%) | $87.37 | $1.2M | +28.6% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 18,357127,183 held (−13%) | $88.02 | $1.6M | +27.7% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 3,929123,254 held (−3%) | $89.43 | $351K | +25.7% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 8,562114,692 held (−7%) | $90.12 | $772K | +24.7% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 3,300111,392 held (−3%) | $91.46 | $302K | +22.9% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 1,400109,992 held (−1%) | $92.19 | $129K | +21.9% |
| Oct 15SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 29,264140,304 held (−17%) | $60.37 | $1.8M | +86.2% |
| Oct 15SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 8,963131,341 held (−6%) | $61.49 | $551K | +82.8% |
| Oct 15SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 14,896116,445 held (−11%) | $62.72 | $934K | +79.2% |
| Oct 15SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 6,453109,992 held (−6%) | $63.09 | $407K | +78.2% |
| Oct 14SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 3,114118,359 held (−3%) | $60.00 | $187K | +87.3% |
- Sell
Chief Medical Officer Jared Gollob sold $1.2M of KYMR at $87.37 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Jared Gollob sold $1.6M of KYMR at $88.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Jared Gollob sold $351K of KYMR at $89.43 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Jared Gollob sold $772K of KYMR at $90.12 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Jared Gollob sold $302K of KYMR at $91.46 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Jared Gollob sold $129K of KYMR at $92.19 — pre-scheduled 10b5-1 plan sale.